Source comparison
Thymosin Alpha-1 with Alcohol Safety: Comparison Table
Abstinence during therapy Baseline immune function maintained Full peptide efficacy. No counteracting suppression Continue abstinence through treatment cycle Optimal approach for research outcomes 1 drink, >72 hours from injection Minimal transient dendritic c
This comparison does not assign a generated winner or score.
- Abstinence during therapy
- Baseline immune function maintained
- Full peptide efficacy. No counteracting suppression
- Continue abstinence through treatment cycle
- Optimal approach for research outcomes
- 1 drink, >72 hours from injection
- Minimal transient dendritic cell delay (12–18 hours)
- Negligible reduction in TLR9 activation
- Acceptable if maintained as rare exception
- Low-risk if timing is strictly controlled
- 2–3 drinks within 48 hours of injection
- T-cell suppression 22–31%, NK activity reduced 30–50%
- Moderate reduction in IL-2 pathway activation
- Avoid entirely during active therapy
- Undermines core therapeutic mechanism
- Chronic use (7+ drinks/week)
- Baseline IL-2 receptor downregulation 25–40%
- Requires 30–40% higher dose for comparable effect
- Discontinue alcohol or delay therapy
- Therapy unlikely to achieve intended outcomes
- Binge episode (BAC ≥0.08%)
- Dendritic MHC-II reduced 18%, immune suppression persists 72+ hours
- Severe temporary loss of peptide efficacy
- Pause therapy until 96-hour washout complete
- Single episode can negate week of treatment